Hypha Labs (FUNI) 10-K/A 18 Jan 24 2023 FY Annual report (amended) Financial data

Cover

Cover - USD ($)	12 Months Ended
	Sep. 30, 2023	Jan. 16, 2024	Mar. 31, 2023
Cover [Abstract]
Document Type	10-K/A
Amendment Flag	true
Amendment Description	Digipath, Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-K/A (the “Amended Report”) to amend its Annual Report for the year ended September 30, 2023, that was originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 16, 2024 (the “Original Report”), to correct the audit opinion of the predecessor auditor. Consequently, the previously filed consolidated financial statements for the year ended September 30, 2022, should no longer be relied upon
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--09-30
Entity File Number	000-54239
Entity Registrant Name	DIGIPATH, INC.
Entity Central Index Key	0001502966
Entity Tax Identification Number	27-3601979
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	6450 Cameron Street
Entity Address, Address Line Two	Suite 113
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89118
City Area Code	(702)
Local Phone Number	527-2060
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 604,532
Entity Common Stock, Shares Outstanding		87,096,820
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Auditor Firm ID	2738
Auditor Name	M&K CPAS, PLLC
Auditor Location	The Woodlands, Texas

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2023	Sep. 30, 2022
Current assets:
Cash	$ 271,006	$ 56,168
Note receivable		100,000
Other current assets	8,570	12,739
Assets held for sale - current	486,222	393,197
Total current assets	765,798	562,104
Fixed assets, net		55,000
Assets held for sale – long term	643,666	722,784
Total non-current assets	643,666	777,784
Total Assets	1,409,464	1,339,888
Current liabilities:
Accounts payable	122,094	200,558
Current maturities of notes payable	565,000	665,000
Liabilities held for sale - current	368,655	477,274
Total current liabilities	3,121,814	2,953,909
Non-current liabilities:
Liabilities held for sale – long term	159,156	310,253
Total non-current liabilities	159,156	795,251
Total Liabilities	3,280,970	3,749,160
Commitments and contingent liabilities
Series B convertible preferred stock, $0.001 par value, 1,500,000 shares authorized; 333,600 shares issued and outstanding as of September 30, 2023 and 2022	333,600	333,600
Stockholders’ Deficit:
Common stock, $0.001 par value, 250,000,000 shares authorized; 87,096,820 and 75,146,820 shares issued and outstanding at September 30, 2023 and 2022, respectively	87,097	75,147
Common stock payable		71,745
Additional paid-in capital	17,468,746	17,117,958
Accumulated deficit	(19,761,997)	(20,008,771)
Total Stockholders’ Deficit	(2,205,106)	(2,742,872)
Total Liabilities and Stockholders’ Deficit	1,409,464	1,339,888
Series A Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock value	1,048	1,048
Series C Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock value		1
Nonrelated Party [Member]
Current liabilities:
Accrued expenses – related party	328,491	219,797
Current maturities of convertible notes payable related parties, net of discounts	1,385,932	1,198,469
Non-current liabilities:
Convertible notes payable, net of discounts and current maturities		174,726
Related Party [Member]
Current liabilities:
Accrued expenses – related party	12,390	192,811
Current maturities of convertible notes payable related parties, net of discounts	339,252
Non-current liabilities:
Convertible notes payable, net of discounts and current maturities		$ 310,272

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2023	Sep. 30, 2022
Preferred stock, par value	$ 0.001
Preferred stock, shares authorized	10,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	87,096,820	75,146,820
Common stock, shares outstanding	87,096,820	75,146,820
Series B Convertible Preferred Stock [Member]
Temporary equity, par value	$ 0.001	$ 0.001
Temporary equity, shares authorized	1,500,000	1,500,000
Temporary equity, shares issued	333,600	333,600
Temporary equity, shares outstanding	333,600	333,600
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	6,000,000	6,000,000
Preferred stock, shares issued	1,047,942	1,047,942
Preferred stock, shares outstanding	1,047,942	1,047,942
Series C Convertible Preferred Stock [Member]
Temporary equity, shares issued	1,000
Temporary equity, shares outstanding	1,000
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000	1,000
Preferred stock, shares issued	0	1,000
Preferred stock, shares outstanding	0	1,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Revenues
Cost of sales
Gross profit
Operating expenses:
General and administrative	103,298	495,762
Professional fees	334,090	654,703
Total operating expenses	437,388	1,150,465
Operating loss	(437,388)	(1,150,465)
Other income (expense):
Interest expense	(364,267)	(244,586)
Other expense	(55,000)
Recovery of previously written off receivables	175,000
Credit loss		(782,500)
Total other income (expense)	(244,267)	(1,027,086)
Net loss from continuing operations	(681,655)	(2,177,551)
Net income (loss) from discontinued operations	928,429	120,433
Net income (loss)	246,774	(2,057,118)
Preferred deemed dividend		(192,154)
Net income (loss) to common shareholders	$ 246,774	$ (2,249,272)
Net loss per share from continuing operations - basic	$ (0.01)	$ (0.03)
Net loss per share from continuing operations - diluted	(0.01)	(0.03)
Net income per share from discontinued operations - basic	0.01	0
Net income per share from discontinued operations - diluted	0.01	0
Net loss per share - basic	0	(0.03)
Net loss per share - diluted	$ 0	$ (0.03)
Weighted average number of common shares outstanding - basic	83,925,450	74,173,304
Weighted average number of common shares outstanding - fully diluted	83,925,450	74,173,304

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Preferred Stock [Member] Series A Convertible Preferred Stock [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member]	Common Stock [Member]	Stock Payable [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Sep. 30, 2021		$ 1,326		$ 71,230		$ 16,825,765	$ (17,951,653)	$ (1,053,332)
Balance, shares at Sep. 30, 2021		1,325,942		71,230,153
Purchase of Series B Preferred shares, shares	55,600
Conversion of Series A Preferred into Series B Preferred	$ 278,000	$ (278)				$ (85,568)		$ (85,846)
Conversion of Series A Preferred Shares into Series B Preferred, shares	278,000	(278,000)
Issuance of Preferred C Shares			$ 1			360,299		360,300
Issuance of Preferred C Shares, shares			1,000
Common stock issued for settlement of accounts payable				$ 250		7,250		7,500
Common Shares issued for settlement of accounts payable, shares				250,000
Common stock issued for services				$ 3,667		139,833		143,500
Common stock issued for services, shares				3,666,667
Common shares to be issued for debt discount					71,745			71,745
Stock-based compensation						62,533		62,533
Deemed dividend on preferred exchange						(192,154)		(192,154)
Net income (loss)							(2,057,118)	(2,057,118)
Balance at Sep. 30, 2022	$ 333,600	$ 1,048	$ 1	$ 75,147	71,745	17,117,958	(20,008,771)	(2,742,872)
Balance, shares at Sep. 30, 2022	333,600	1,047,942	1,000	75,146,820
Net income (loss)							246,774	246,774
Repurchase of Series C Preferred shares			$ (1)			(99)		(100)
Repurchased of Series C Preferred shares, shares			(1,000)
Common stock issued for settlement of stock payable				$ 7,150	(71,745)	64,595
Common stock issued for settlement of stock payable, shares				7,150,000
Common stock issued for compensation				$ 4,800		29,880		34,680
Common stock issued for compensation, shares				4,800,000
Warrants issued for debt financing costs						93,938		93,938
Stock-based compensation						24,474		24,474
Forgiveness of accrued director compensation						138,000		138,000
Balance at Sep. 30, 2023	$ 333,600	$ 1,048		$ 87,097		$ 17,468,746	$ (19,761,997)	$ (2,205,106)
Balance, shares at Sep. 30, 2023	333,600	1,047,942		87,096,820

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities
Net loss from continuing operations	$ (681,655)	$ (2,177,551)
Adjustments to reconcile net loss to net cash used in operating activities:
Recovery of previously written off receivables	(175,000)
Credit loss		782,500
Stock-based compensation	59,154	566,233
Amortization of debt discounts	135,655	85,166
Impairment of fixed assets	55,000
Decrease (increase) in assets:
Other current assets	4,169	(813)
Increase (decrease) in liabilities:
Accounts payable	(78,465)	77,601
Accrued expenses	108,694	54,172
Accrued expenses – related parties	(42,421)	150,811
Net cash (used in) operating activities from continuing operations	(614,869)	(461,881)
Net cash provided by operating activities from discontinued operations	727,394	277,095
Net cash provided by (used in) operating activities	112,525	(184,786)
Cash flows from investing activities
Advance of note receivable		(817,649)
Proceeds from sale of collateralized assets	275,000	175,000
Net cash (used) in investing activities from continuing operations	275,000	(642,649)
Net cash (used) in investing activities from discontinued operations	(11,667)	(17,722)
Net cash (used) in investing activities	263,333	(660,371)
Cash flows from financing activities
Proceeds from notes payable		390,000
Repayments of notes payable	(100,000)	(125,000)
Proceeds from convertible notes		402,765
Repayments on convertible notes		(40,000)
Proceeds from sale of preferred stock		55,600
Repurchase of preferred C stock	(100)
Net cash provided by (used in) financing activities	(100,100)	683,365
Net cash used in financing activities from discontinued operations	(60,920)	(77,972)
Net cash provided by (used in) financing activities	(161,020)	605,393
Net increase (decrease) in cash	214,838	(239,764)
Cash - beginning	56,168	295,932
Cash - ending	271,006	56,168
Supplemental disclosures:
Interest paid	227,691	113,817
Income taxes paid
Non-cash investing and financing activities:
Common stock issued for settlement of payables		7,500
Conversion of Series A preferred into Series B preferred		85,846
Deemed dividend on preferred exchange		192,154
Subscription receivable for Series C preferred stock		100
Stock payable issued for debt discounts on convertible notes payable		71,745
Common stock issued for settlement of stock payable	71,745
Transfer of completed assets	6,076
Warrants issued for debt financing	93,938
Common stock issued for settlement of related party accrued compensation	$ 138,000

Nature of Business and Signific

Nature of Business and Significant Accounting Policies	12 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Nature of Business and Significant Accounting Policies	Note 1 – Nature of Business and Significant Accounting Policies Nature of Business Digipath, Inc. was incorporated in Nevada on October 5, 2010. Digipath, Inc. and its subsidiaries (“Digipath,” the “Company,” “we,” “our” or “us”) is a service-oriented independent testing laboratory and data analytics company focused on the developing cannabis and hemp markets, and supports the cannabis industry’s best practices for reliable testing. Our mission is to provide pharmaceutical-grade analysis and testing to the cannabis industry, under ISO-17025:2017 guidelines, to ensure consumers and patients know exactly what is in the cannabis they ingest and to help maximize the quality of our clients’ products through research, development, and standardization. Digipath has been operating a cannabis-testing lab in Nevada serving Nevada since 2015. Basis of Accounting The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (“SEC”). Intercompany accounts and transactions have been eliminated. All references to Generally Accepted Accounting Principles (“GAAP”) are in accordance with The FASB Accounting Standards Codification (“ASC”) and the Hierarchy of Generally Accepted Accounting Principles. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at September 30, 2023: Schedule of Entities Under Common Control and Ownership Jurisdiction of Name of Entity Incorporation Relationship Digipath, Inc (1) Nevada Parent Digipath Labs, Inc Nevada Subsidiary Digipath Labs CA, Inc (2) California Subsidiary Digipath Labs S.A.S (3) Colombia Subsidiary VSSL Enterprises, Ltd (4) Canada Subsidiary (1) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (2) Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations and has no significant assets. (3) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations and has no significant assets. (4) Acquired on March 11, 2020. The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “Digipath” or “DIGP”. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its customers are within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Segment Reporting ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations. Fair Value of Financial Instruments The Company adopted ASC 820, Fair Value Measurements and Disclosures (“ASC 820”). ASC 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows: - Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. - Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. - Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement. The carrying value of cash, accounts receivable, accounts payables and accrued expenses are estimated by management to approximate fair value primarily due to the short term nature of the instruments. Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. The Company had an allowance for doubtful accounts of $ 154,179 and $ 139,279 as of September 30, 2023 and 2022, respectively. Assets held for sale – current Notes Receivable Notes receivable are reported in our consolidated balance sheets at the outstanding principal balance, plus costs incurred to originate the loans, net of any unamortized premiums or discounts on purchased loans. We use the effective interest rate method to recognize finance income, which produces a constant periodic rate of return on the investment. Unearned income, discounts and premiums are amortized to finance income in our consolidated statements of operations using the effective interest rate method. Interest receivable related to the unpaid principal is recorded together with the outstanding balance in our consolidated balance sheets. Upon the prepayment of a note receivable, any prepayment penalties and unamortized loan origination, closing and commitment fees are recorded as part of finance income in our consolidated statements of operations. Notes receivable are periodically evaluated for collectability based on past credit history with note holders and their current financial condition. The Company had an allowance for credit losses of $ 720,000 931,665 Fixed Assets Fixed assets are stated at the lower of cost or estimated net recoverable amount. The cost of property, plant and equipment is depreciated using the straight-line method based on the lesser of the estimated useful lives of the assets or the lease term based on the following life expectancy: Schedule of Estimated Useful Lives of Property, Plant and Equipment Software 3 Office equipment 5 Furniture and fixtures 5 Lab equipment 7 Leasehold improvements Term of lease Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation and amortization are eliminated and any resulting gain or loss is reflected in operations. As of September 30, 2023, fixed assets are classified as Assets held for sale – long term Impairment of Long-Lived Assets Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or circumstances indicate the carrying amount of an asset may not be recoverable or is impaired. Recoverability is assessed using undiscounted cash flows based upon historical results and current projections of earnings before interest and taxes. Impairment is measured using discounted cash flows of future operating results based upon a rate that corresponds to the cost of capital. Impairments are recognized in operating results to the extent that carrying value exceeds discounted cash flows of future operations. Our intellectual property is comprised of indefinite-lived brand names acquired and have been assigned an indefinite life as we currently anticipate that these brand names will contribute cash flows to the Company perpetually. We evaluate the recoverability of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired. Revenue Recognition The Company recognizes revenue in accordance with ASC 606 - Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. Our revenue is primarily generated through our subsidiary, Digipath Labs, Inc., which recognizes revenue from the analytical testing of cannabis products for licensed producers and cultivators within the state of Nevada on a determinable fixed fee per test, or panel of tests, basis. Revenue from the performance of those services is recognized upon completion of the tests, at which time test results are delivered to the customer, provided collectability of the fee is reasonably assured. We typically require payment within thirty days of the delivery of results. As of September 30, 2023 and 2022, all revenues are classified as part of Net income from discontinued operations Discontinued Operations On April 20, 2023, the Company and Digipath Labs entered into an Asset Purchase Agreement (the “Purchase Agreement”) with DPL NV, LLC (“Buyer”), pursuant to which Digipath Labs has agreed to sell substantially all of its assets to Buyer for a cash purchase price of $ 2,300,000 Assets and liabilities of the discontinued operations are aggregated and reported separately as assets and liabilities of discontinued operations in the Consolidated Balance Sheets as of September 30, 2023 and 2022. The results of discontinued operations are aggregated and presented separately in the Consolidated Statements of Operations as net income from discontinued operations for the years ended September 30, 2023 and 2022. The cash flows of the discontinued operations are reflected as cash flows of discontinued operations within the Company’s Consolidated Statements of Cash Flows for the years ended September 30, 2023 and 2022. Amounts presented in discontinued operations have been derived from our consolidated financial statements and accounting records using the historical basis of assets, liabilities, results of operations, and cash flows of Digipath Labs. The discontinued operations exclude general corporate allocations. Advertising Costs The Company expenses the cost of advertising and promotions as incurred. Advertising and promotions expense was $ 4,444 58,739 Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the years ended September 30, 2023 and 2022, potential dilutive securities of 83,125,488 58,941,155 8,120,000 6,020,000 15,387,050 1,500,000 13,579,710 13,579,710 Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 2018-07 (ASC 2018-07). All transactions in which the consideration provided in exchange for the purchase of goods or services consists of the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance. Income Taxes The Company recognizes deferred tax assets and liabilities based on differences between the financial reporting and tax basis of assets and liabilities using the enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered. The Company provides a valuation allowance for deferred tax assets for which it does not consider realization of such assets to be more likely than not. Uncertain Tax Positions In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions. Reclassifications Certain reclassifications have been made to the prior period financial statements to conform to the current period presentation. These reclassifications had no effect on our previously reported results of operations or accumulated deficit. Recently Issued Accounting Pronouncements There are no recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

Going Concern

Going Concern	12 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 2 – Going Concern As shown in the accompanying consolidated financial statements, the Company has incurred recurring losses from operations resulting in an accumulated deficit of $ 19,761,997 The consolidated financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. These financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Sep. 30, 2023
Investments, All Other Investments [Abstract]
Fair Value of Financial Instruments	Note 3 – Fair Value of Financial Instruments Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value. The Company has certain financial instruments that must be measured under the new fair value standard. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of September 30, 2023 and 2022, respectively: Summary of Financial Instruments at Fair Value on Recurring Basis Level 1 Level 2 Level 3 Fair Value Measurements at September 30, 2023 Level 1 Level 2 Level 3 Assets Cash $ 271,006 $ - $ - Liabilities Notes payable - 565,000 - Convertible notes payable, net of discounts of $ 43,051 - - 1,725,184 Level 1 Level 2 Level 3 Fair Value Measurements at September 30, 2022 Level 1 Level 2 Level 3 Assets Cash $ 56,168 $ - $ - Liabilities Notes payable - 665,000 - Convertible notes payable, net of discounts of $ 84,767 - - 1,683,467 The fair value of our intellectual properties is deemed to approximate book value, and are considered Level 3 inputs as defined by ASC Topic 820-10-35. There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the years ended September 30, 2023 or 2022.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Note 4 – Related Party Transactions During the year ended September 30, 2023 the Company incurred compensation expense of $ 60,000 111,437 During the year ended September 30, 2023 the Company incurred fees of $ 34,000 30,000 138,000 10,000 As of September 30, 2023, the Company has accrued a total of $ 2,390 During the year ended September 30, 2023, the Company granted 3,400,000 1,400,000 24,820 9,860

Note Receivable

Note Receivable	12 Months Ended
	Sep. 30, 2023
Receivables [Abstract]
Note Receivable	Note 5 – Note Receivable On various dates between December 28, 2018 and June 13, 2019, we loaned Northwest Analytical Labs, Inc. a total of $ 95,000 10 On various dates between August 23, 2021 and September 30, 2022, we loaned C3 Labs, Inc. (“C3 Labs”) a total of $ 1,056,570 8 August 23, 2022 64,017 The loans were made in connection with a potential acquisition of a controlling interest in C3 Labs pursuant to a letter of intent. On March 11, 2022, the Company notified the current owners of C3 Labs of its termination of the letter of intent and took possession of the equipment of C3 Labs (“C3 Equipment”). On December 8, 2022, the Company entered into an Asset Purchase Agreement with Invictus Wealth Group (“Invictus”), whereby the Company agreed to sell the C3 Equipment to Invictus for a total purchase price of $ 900,000 275,000 625,000 December 31, 2023 10 100,000 425,000 275,000 100,000 425,000

Fixed Assets

Fixed Assets	12 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Fixed Assets	Note 6 – Fixed Assets Fixed assets consist of the following at September 30, 2023 and 2022: Schedule of Fixed Assets 2023 2022 As of September 30, September 30, 2023 2022 Lab equipment $ - $ 55,000 Fixed assets, gross - 55,000 Less: accumulated depreciation - - Total $ - $ 55,000 During the year ended September 30, 2023, the Company recorded impairment expense in the amount of $ 55,000

Notes Payable

Notes Payable	12 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Notes Payable	Note 7 – Notes Payable Notes payable consists of the following at September 30, 2023 and 2022, respectively: Schedule of Notes Payable September 30, September 30, On September 10, 2021, the Company issued a Secured Promissory note in the principal amount of $ 675,000 12 September 10, 2024 22,419.66 115,000 125,000 $ 665,000 $ 665,000 Total notes payable 665,000 665,000 Less: current maturities (665,000 ) (665,000 ) Notes payable $ - $ - The Company recorded interest expense pursuant to the stated interest rate and closing costs on the notes payable in the amount of $ 79,800 45,444 Notes payable – discontinued operations On December 26, 2019, the Company financed the purchase of $ 377,124 291,931 5.75 5,622 five-year December 26, 2024 $ 80,428 $ 141,348

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Convertible Notes Payable	Note 8 – Convertible Notes Payable Related party convertible notes payable consist of the following at September 30, 2023 and September 30, 2022, respectively: Schedule of Related Party Convertible Notes Payable September 30, September 30, 2023 2022 On February 10, 2020, the Company completed the sale to an accredited investor of a 9% Secured Convertible Promissory Note in the principal amount of $ 350,000 August 10, 2022 9 0.15 0.03 50,000 400,000 50,000 1,666,667 0.03 February 11, 2024 4,550,000 43,788 As a result of the shares issued upon the extension agreement, the lender now holds more the 5% of the total outstanding common shares, and is therefore considered a related party $ 350,000 $ 350,000 Total related party convertible notes payable 350,000 350,000 Less: unamortized debt discounts (10,748 ) (39,728 ) Total convertible debt 339,252 310,272 Less: current maturities (339,252 ) - Related party convertible notes payable $ - $ 310,272 Convertible notes payable consist of the following at September 30, 2023 and 2022, respectively: Schedule of Convertible Notes Payable September 30, September 30, 2023 2022 On February 11, 2020, the Company completed the sale to an accredited investor of a 9% Secured Convertible Promissory Note in the principal amount of $ 50,000 August 11, 2022 9 0.15 0.03 10,000 60,000 10,000 333,334 0.03 February 11, 2024 650,000 6,989 $ 50,000 $ 50,000 On February 11, 2020, the Company completed the sale to an accredited investor of a 9% Secured Subordinated Convertible Promissory Note in the principal amount of $ 150,000 August 11, 2022 9 0.15 0.03 50,000 200,000 50,000 1,666,667 0.03 February 11, 2024 1,950,000 20,968 150,000 150,000 On September 23, 2019, the Company received proceeds of $ 200,000 8 August 10, 2022 0.11 August 10, 2022 0.03 90,000 3,000,000 0.03 355,469 98,188 February 11, 2024 4,621,105 32,166 355,469 355,469 On November 8, 2018, the Company received proceeds of $ 350,000 8 August 10, 2022 0.14 August 10, 2022 0.03 February 11, 2024 4,550,000 31,671 350,000 350,000 On October 1, 2022, the Company entered into a senior secured convertible note that carries an 8 February 11, 2024 362,765 0.01 4,715,945 30,102 362,765 362,765 On November 5, 2018, the Company received proceeds of $ 150,000 8 August 10, 2022 0.14 August 10, 2022 0.03 150,000 150,000 Total convertible notes payable 1,418,234 1,418,234 Less: unamortized debt discounts (32,302 ) (45,039 ) Total convertible debt 1,385,932 1,373,195 Less: current maturities (1,385,932 ) (1,198,469 ) Convertible notes payable $ - $ 174,726 In addition, the Company recognized and measured the embedded beneficial conversion feature present in the convertible notes by allocating a portion of the proceeds equal to the intrinsic value of the feature to additional paid-in-capital. The intrinsic value of the feature was calculated on the commitment date using the effective conversion price of the convertible notes. This intrinsic value is limited to the portion of the proceeds allocated to the convertible debt. The aforementioned accounting treatment resulted in a total debt discount equal to $ 93,938 135,655 85,166 43,050 All of the convertible notes limit the maximum number of shares that can be owned by each note holder as a result of the conversions to common stock to 4.99 The Company recorded interest expense pursuant to the stated interest rates on the convertible notes in the amount of $ 148,812 113,976 The Company recognized interest expense for the years ended September 30, 2023 and 2022, respectively, as follows: Schedule of Interest Expense September 30, September 30, Interest on notes payable $ 79,800 $ 45,444 Amortization of beneficial conversion features 135,655 85,166 Interest on convertible notes 148,812 113,976 Total interest expense $ 364,267 $ 244,586

Stockholders_ Equity

Stockholders’ Equity	12 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Stockholders’ Equity	Note 9 – Stockholders’ Equity Preferred Stock The Company is authorized to issue 10,000,000 0.001 6,000,000 1,500,000 1,000 2,499,000 1,047,942 333,600 1,000 Series A Preferred The conversion price is adjustable in the event of stock splits and other adjustments in the Company’s capitalization, and in the event of certain negative actions undertaken by the Company. At the current conversion price, the 1,047,942 5,239,710 No holder is permitted to convert its shares of Series A Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice Additional terms of the Series A Preferred include the following: ● The shares of Series A Preferred are entitled to dividends when, as and if declared by the Board as to the shares of the common stock of the Company into which such Series A Preferred may then be converted, subject to the 4.99 ● Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, the shares of Series A Preferred are entitled to receive, prior to any distribution to the holders of common stock, 100 ● The Series A Preferred plus all declared but unpaid dividends thereon automatically will be converted into common stock, at the then applicable conversion rate, upon the affirmative vote of the holders of a majority of the outstanding shares of Series A Preferred. ● Each share of Series A Preferred will carry a number of votes equal to the number of shares of common stock into which such Series A Preferred may then be converted, subject to the 4.99 ● Consent of the holders of the outstanding Series A Preferred is required in order for the Company to: (i) amend or change the rights, preferences, privileges or powers of, or the restrictions provided for the benefit of, the Series A Preferred; (ii) authorize, create or issue shares of any class of stock having rights, preferences, privileges or powers superior to the Series A Preferred; (iii) reclassify any outstanding shares into shares having rights, preferences, privileges or powers superior to the Series A Preferred; or (iv) amend the Company’s Articles of Incorporation or Bylaws in a manner that adversely affects the rights of the Series A Preferred. ● Pursuant to the Securities Purchase Agreements, holders of Series A Preferred are entitled to unlimited “piggyback” registration rights on registrations by the Company, subject to pro rata cutback at any underwriter’s discretion. During the year ended September 30, 2022, the Company offered to the Series A Preferred shareholders the ability to convert their Series A Preferred shares into Series B Preferred shares for an additional investment of 20 55,600 55,600 278,000 192,154 Series C Preferred The Series C Preferred stock was designated on July 20, 2022. The principal feature of the Series C Preferred is that it provides the holder thereof, so long as he or she is an executive officer of the Company, with the ability to vote with the holders of the Company’s common stock on all matters presented to the holders of common stock, whether at a special or annual meeting, by written action in lieu of a meeting or otherwise, on the basis of 200,000 votes for each share of Series C Preferred 0.10 On July 25, 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Todd Denkin, the Company’s President, pursuant to which Mr. Denkin purchased 1,000 0.10 360,200 On March 2, 2023, the Company entered into a Preferred Stock Repurchase Agreement with Todd Denkin, the Company’s president, pursuant to which Mr. Denkin surrendered his Series C Preferred back to the Company for the purchase price of $ 100 Common Stock The common stock has a par value of $ 0.001 250,000,000 87,096,820 Common Stock Transactions for the Year Ended September 30, 2023 During the year ended September 30, 2023, the Company issued 7,150,000 71,745 During the year ended September 30, 2023, the Company granted 3,400,000 1,400,000 24,820 9,860 Common Stock Transactions for the Year Ended September 30, 2022 During the year ended September 30, 2022, the Company issued 1,500,000 52,500 During the year ended September 30, 2022, the Company issued 2,166,667 91,000 During the year ended September 30, 2022, the Company issued 250,000 7,500 In connection with the Convertible Note extensions as described in Note 8, the Company was to issue 7,150,000 71,745 Amortization of Stock-Based Compensation A total of $ 143,500 3,666,667

Mezzanine Equity

Mezzanine Equity	12 Months Ended
	Sep. 30, 2023
Mezzanine Equity
Mezzanine Equity	Note 10 – Mezzanine Equity Series B Preferred The shares of Series B Preferred were designated on December 29, 2021. Each share of Series B Preferred has a Stated Value of $ 1.00 0.04 333,600 8,340,000 No holder is permitted to convert its shares of Series B Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice Additional terms of the Series B Preferred include the following: ● The shares of Series B Preferred are not entitled to dividends, provided that if dividends are paid on the shares of common stock of the Company, the Series B Preferred will be entitled to dividends based on the number shares of common stock which the Series B Preferred may then be converted. ● Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, or upon a change in control whereby a stockholder gains control of 50% or more of the outstanding shares of common stock, the shares of Series B Preferred are entitled to receive, prior to any distribution to the holders of common stock and the Series A Preferred, 100% of the purchase price per share of Series B Preferred plus all accrued but unpaid dividends ● Each share of Series B Preferred carries a number of votes equal to the number of shares of common stock into which such Series B Preferred may then be converted. Due to the change in control provision of the Series B Preferred, the Series B Preferred is classified as temporary equity on the balance sheet. On December 30, 2021, the Company entered into an Exchange Agreement with one of the Company’s institutional investors (the “Investor”), pursuant to which the Investor exchanged 278,000 278,000 55,600 1.00 55,600

Common Stock Options

Common Stock Options	12 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Common Stock Options	Note 11 – Common Stock Options Stock Incentive Plan On June 21, 2016, we amended and restated our 2012 Stock Incentive Plan (the “2012 Plan”), which was originally adopted on March 5, 2012, and terminated on March 5, 2022. As amended, the 2012 Plan provides for the issuance of up to 11,500,000 Common Stock Option Issuances During the year ended September 30, 2023, the Company issued to certain employees, options to purchase 2,100,000 10,446 184 0.00497 0.0056 5.75 During the year ended September 30, 2022, the Company issued to an unrelated third party, options to purchase 1,000,000 20,994 143 0.021 0.024 Amortization of Stock-Based Compensation A total of $ 24,474 62,533 1,153 The following is a summary of information about the stock options outstanding at September 30, 2023. Summary of Common Stock Options Outstanding Shares Underlying Shares Underlying Options Outstanding Options Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Options Contractual Exercise Options Exercise Prices Outstanding Life Price Exercisable Price $ 0.0056 0.13 8,120,000 5.03 $ 0.052 6,020,000 $ 0.069 The fair value of each option grant is estimated on the date of grant using the Black-Scholes Option Pricing Model with the following weighted-average assumptions used for grants under the fixed option plan: Schedule of Weighted-Average Assumptions Used for Grants September 30, September 30, 2023 2022 Average risk-free interest rates 3.88 % 1.21 % Average expected life (in years) 2.9 5.00 Volatility 184.34 % 143 % The Black-Scholes Option Pricing Model was developed for use in estimating the fair value of short-term traded options that have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including expected stock price volatility. Because the Company’s common stock options have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion the existing models do not necessarily provide a reliable single measure of the fair value of its common stock options. During the years ended September 30, 2023 and September 30, 2022, there were no options granted with an exercise price below the fair value of the underlying stock at the grant date. The weighted average fair value of options granted with exercise prices at the current fair value of the underlying stock during the year ended September 30, 2023 was approximately $ 0.005 The following is a summary of activity of outstanding common stock options: Schedule of Activity of Outstanding Common Stock Options Weighted Average Number Exercise of Shares Price Balance, September 30, 2021 5,620,000 $ 0.08 Options issued 1,000,000 0.02 Options repurchased/expired (600,000 ) (0.11 ) Balance, September 30, 2022 6,020,000 $ 0.069 Options issued 2,100,000 0.006 Options forfeited - - Balance, September 30, 2023 8,120,000 $ 0.052 Exercisable, September 30, 2023 6,020,000 $ 0.069 As of September 30, 2023, these options in the aggregate had $ 19,320 0.015

Common Stock Warrants

Common Stock Warrants	12 Months Ended
	Sep. 30, 2023
Common Stock Warrants
Common Stock Warrants	Note 12 – Common Stock Warrants Warrants to purchase a total of 15,387,050 During the year ended September 30, 2023, warrants to purchase an aggregate total of 13,887,050 0.007 During the year ended September 30, 2022, warrants to purchase an aggregate total of 1,035,001 0.26 The following is a summary of information about our warrants to purchase common stock outstanding at September 30, 2023 (including those issued to both investors and service providers). Summary of Common Stock Warrants Outstanding Shares Underlying Shares Underlying Warrants Outstanding Warrants Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Warrants Contractual Exercise Warrants Exercise Prices Outstanding Life Price Exercisable Price $ 0.0074 0.10 15,387,050 8.76 $ 0.016 15,387,050 $ 0.016 The fair value of each warrant grant is estimated on the date of grant using the Black-Scholes Option Pricing Model with the following weighted-average assumptions used for grants under the fixed option plan: The following is a summary of activity of outstanding common stock warrants: Schedule of Outstanding Common Stock Warrants Activity Weighted Average Number Exercise of Shares Price Balance, September 30, 2021 2,535,001 $ 0.17 Warrants granted - - Warrants expired (1,035,001 ) (0.26 ) Balance, September 30, 2022 1,500,000 $ 0.10 Warrants granted 13,887,050 .007 Warrants expired - - Balance, September 30, 2023 15,387,050 $ 0.016 Exercisable, September 30, 2023 15,387,050 $ 0.016 As of September 30, 2023, these warrants in the aggregate had $ 102,764 0.015

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 13 – Commitments and Contingencies Legal Contingencies There are no material pending legal proceedings to which we are a party or to which any of our property is subject, nor are there any such proceedings known to be contemplated by governmental authorities. None of our directors, officers or affiliates is involved in a proceeding adverse to our business or has a material interest adverse to our business.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Sep. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Note 14 – Discontinued Operations On April 20, 2023, the Company, and Digipath Labs entered into the Purchase Agreement with DPL NV, LLC (“Buyer”), pursuant to which Digipath Labs has agreed to sell substantially all of its assets to Buyer for a cash purchase price of $ 2,300,000 150,000 The Purchase Agreement includes a number of representations, warrantees, covenants and conditions to closing customary for this type of transaction. In addition, the closing of the transaction is subject to the approval of the Nevada Cannabis Compliance Board (the “CCB”). In the event CCB approval is not obtained by June 30, 2024, or any other condition to closing has not been satisfied by such date, either party may terminate the Purchase Agreement. Pursuant to the Purchase Agreement, the Buyer deposited $ 230,000 In connection with the transactions contemplated by the Purchase Agreement, Digipath, Digipath Labs and Buyer entered into a Management Services Agreement (the “Management Services Agreement”), dated as of April 30, 2023, pursuant to which Buyer has been engaged to manage the operation of Digipath Labs’ cannabis testing laboratory (the “Lab”). The effectiveness of the Management Services Agreement is subject to the approval of the CCB, which was obtained on October 17, 2023. Pursuant to the Management Services Agreement, after the payment of expenses to third parties and a payment of 15% of cash collections to Digipath (but not less than $ 15,000 10,000 The balance sheets of Digipath Labs are summarized below: Schedule of Discontinued Operations Income Statement Balance Sheet and Additional Disclosures September 30, 2023 September 30, 2022 Current assets: Accounts receivable, net $ 447,410 $ 335,085 Deposits 18,675 25,141 Other current assets 20,137 32,971 Total current assets 486,222 393,197 Right-of-use asset 274,985 316,961 Fixed assets, net 368,681 405,823 Total long term assets 643,666 722,784 Total Assets $ 1,129,888 $ 1,115,981 Current liabilities: Accounts payable $ 158,869 $ 283,098 Accrued expenses 61,512 32,571 Current portion of operating lease liabilities 83,757 100,685 Current maturities of notes payable 64,517 60,920 Total current liabilities 368,655 477,274 Operating lease liabilities 143,245 229,825 Notes payable 15,911 80,428 Total long term liabilities 159,156 310,253 Total Liabilities $ 527,811 $ 787,527 The statements of operations of Digipath Labs combined are summarized below: 2023 2022 For the Years Ended September 30, 2023 2022 Revenues $ 3,330,704 $ 2,699,920 Cost of sales 1,736,401 1,633,972 Gross profit 1,594,303 1,065,948 Operating expenses: General and administrative 883,781 927,671 Professional fees 98,352 2,157 Total operating expenses 982,133 929,828 Operating income(loss) 612,170 136,120 Other income (expense): Other income 322,798 - Interest expense (6,539 ) (15,687 ) Total other income (expense) 316,259 (15,687 ) Net income (loss) $ 928,429 $ 120,433

Income Tax

Income Tax	12 Months Ended
	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income Tax	Note 15 - Income Tax The Company accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences. For the years ended September 30, 2023 and 2022, the Company incurred a net operating loss and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At September 30, 2023, the Company had approximately $ 14,096,000 2031 The effective income tax rate for the years ended September 30, 2023 and 2022 consisted of the following: Schedule of Effective Income Tax Rate 2023 2022 September 30, 2023 2022 Federal statutory income tax rate 21 % 21 % State income taxes - % - % Change in valuation allowance (21 )% (21 )% Net effective income tax rate - - The components of the Company’s deferred tax asset are as follows: Schedule of Deferred Tax Asset 2023 2022 September 30, 2023 2022 Deferred tax assets: Net operating loss carry forwards $ 2,960,100 $ 3,130,800 Net deferred tax assets before valuation allowance $ 2,960,100 $ 3,130,800 Less: Valuation allowance (2,960,100 ) (3,130,800 ) Net deferred tax assets $ - $ - Based on the available objective evidence, including the Company’s history of its loss, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at September 30, 2023 and 2022, respectively. In accordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no

Subsequent Events

Subsequent Events	12 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 16 – Subsequent Events On October 17, 2023, the CCB approved the Management Services Agreement, dated as of April 30, 2023, pursuant to which the Buyer was engaged to manage the operations of the Company’s cannabis testing laboratory, in connection with the Purchase Agreement. See Note 14.

Nature of Business and Signif_2

Nature of Business and Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Nature of Business	Nature of Business Digipath, Inc. was incorporated in Nevada on October 5, 2010. Digipath, Inc. and its subsidiaries (“Digipath,” the “Company,” “we,” “our” or “us”) is a service-oriented independent testing laboratory and data analytics company focused on the developing cannabis and hemp markets, and supports the cannabis industry’s best practices for reliable testing. Our mission is to provide pharmaceutical-grade analysis and testing to the cannabis industry, under ISO-17025:2017 guidelines, to ensure consumers and patients know exactly what is in the cannabis they ingest and to help maximize the quality of our clients’ products through research, development, and standardization. Digipath has been operating a cannabis-testing lab in Nevada serving Nevada since 2015.
Basis of Accounting	Basis of Accounting The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (“SEC”). Intercompany accounts and transactions have been eliminated. All references to Generally Accepted Accounting Principles (“GAAP”) are in accordance with The FASB Accounting Standards Codification (“ASC”) and the Hierarchy of Generally Accepted Accounting Principles.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at September 30, 2023: Schedule of Entities Under Common Control and Ownership Jurisdiction of Name of Entity Incorporation Relationship Digipath, Inc (1) Nevada Parent Digipath Labs, Inc Nevada Subsidiary Digipath Labs CA, Inc (2) California Subsidiary Digipath Labs S.A.S (3) Colombia Subsidiary VSSL Enterprises, Ltd (4) Canada Subsidiary (1) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (2) Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations and has no significant assets. (3) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations and has no significant assets. (4) Acquired on March 11, 2020. The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “Digipath” or “DIGP”. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its customers are within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
Segment Reporting	Segment Reporting ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company adopted ASC 820, Fair Value Measurements and Disclosures (“ASC 820”). ASC 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows: - Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. - Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. - Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement. The carrying value of cash, accounts receivable, accounts payables and accrued expenses are estimated by management to approximate fair value primarily due to the short term nature of the instruments.
Accounts Receivable	Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. The Company had an allowance for doubtful accounts of $ 154,179 and $ 139,279 as of September 30, 2023 and 2022, respectively. Assets held for sale – current
Notes Receivable	Notes Receivable Notes receivable are reported in our consolidated balance sheets at the outstanding principal balance, plus costs incurred to originate the loans, net of any unamortized premiums or discounts on purchased loans. We use the effective interest rate method to recognize finance income, which produces a constant periodic rate of return on the investment. Unearned income, discounts and premiums are amortized to finance income in our consolidated statements of operations using the effective interest rate method. Interest receivable related to the unpaid principal is recorded together with the outstanding balance in our consolidated balance sheets. Upon the prepayment of a note receivable, any prepayment penalties and unamortized loan origination, closing and commitment fees are recorded as part of finance income in our consolidated statements of operations. Notes receivable are periodically evaluated for collectability based on past credit history with note holders and their current financial condition. The Company had an allowance for credit losses of $ 720,000 931,665
Fixed Assets	Fixed Assets Fixed assets are stated at the lower of cost or estimated net recoverable amount. The cost of property, plant and equipment is depreciated using the straight-line method based on the lesser of the estimated useful lives of the assets or the lease term based on the following life expectancy: Schedule of Estimated Useful Lives of Property, Plant and Equipment Software 3 Office equipment 5 Furniture and fixtures 5 Lab equipment 7 Leasehold improvements Term of lease Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation and amortization are eliminated and any resulting gain or loss is reflected in operations. As of September 30, 2023, fixed assets are classified as Assets held for sale – long term
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or circumstances indicate the carrying amount of an asset may not be recoverable or is impaired. Recoverability is assessed using undiscounted cash flows based upon historical results and current projections of earnings before interest and taxes. Impairment is measured using discounted cash flows of future operating results based upon a rate that corresponds to the cost of capital. Impairments are recognized in operating results to the extent that carrying value exceeds discounted cash flows of future operations. Our intellectual property is comprised of indefinite-lived brand names acquired and have been assigned an indefinite life as we currently anticipate that these brand names will contribute cash flows to the Company perpetually. We evaluate the recoverability of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 606 - Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. Our revenue is primarily generated through our subsidiary, Digipath Labs, Inc., which recognizes revenue from the analytical testing of cannabis products for licensed producers and cultivators within the state of Nevada on a determinable fixed fee per test, or panel of tests, basis. Revenue from the performance of those services is recognized upon completion of the tests, at which time test results are delivered to the customer, provided collectability of the fee is reasonably assured. We typically require payment within thirty days of the delivery of results. As of September 30, 2023 and 2022, all revenues are classified as part of Net income from discontinued operations
Discontinued Operations	Discontinued Operations On April 20, 2023, the Company and Digipath Labs entered into an Asset Purchase Agreement (the “Purchase Agreement”) with DPL NV, LLC (“Buyer”), pursuant to which Digipath Labs has agreed to sell substantially all of its assets to Buyer for a cash purchase price of $ 2,300,000 Assets and liabilities of the discontinued operations are aggregated and reported separately as assets and liabilities of discontinued operations in the Consolidated Balance Sheets as of September 30, 2023 and 2022. The results of discontinued operations are aggregated and presented separately in the Consolidated Statements of Operations as net income from discontinued operations for the years ended September 30, 2023 and 2022. The cash flows of the discontinued operations are reflected as cash flows of discontinued operations within the Company’s Consolidated Statements of Cash Flows for the years ended September 30, 2023 and 2022. Amounts presented in discontinued operations have been derived from our consolidated financial statements and accounting records using the historical basis of assets, liabilities, results of operations, and cash flows of Digipath Labs. The discontinued operations exclude general corporate allocations.
Advertising Costs	Advertising Costs The Company expenses the cost of advertising and promotions as incurred. Advertising and promotions expense was $ 4,444 58,739
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the years ended September 30, 2023 and 2022, potential dilutive securities of 83,125,488 58,941,155 8,120,000 6,020,000 15,387,050 1,500,000 13,579,710 13,579,710
Stock-Based Compensation	Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 2018-07 (ASC 2018-07). All transactions in which the consideration provided in exchange for the purchase of goods or services consists of the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance.
Income Taxes	Income Taxes The Company recognizes deferred tax assets and liabilities based on differences between the financial reporting and tax basis of assets and liabilities using the enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered. The Company provides a valuation allowance for deferred tax assets for which it does not consider realization of such assets to be more likely than not.
Uncertain Tax Positions	Uncertain Tax Positions In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.
Reclassifications	Reclassifications Certain reclassifications have been made to the prior period financial statements to conform to the current period presentation. These reclassifications had no effect on our previously reported results of operations or accumulated deficit.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements There are no recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

Nature of Business and Signif_3

Nature of Business and Significant Accounting Policies (Tables)	12 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Schedule of Entities Under Common Control and Ownership	The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at September 30, 2023: Schedule of Entities Under Common Control and Ownership Jurisdiction of Name of Entity Incorporation Relationship Digipath, Inc (1) Nevada Parent Digipath Labs, Inc Nevada Subsidiary Digipath Labs CA, Inc (2) California Subsidiary Digipath Labs S.A.S (3) Colombia Subsidiary VSSL Enterprises, Ltd (4) Canada Subsidiary (1) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (2) Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations and has no significant assets. (3) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations and has no significant assets. (4) Acquired on March 11, 2020.
Schedule of Estimated Useful Lives of Property, Plant and Equipment	Schedule of Estimated Useful Lives of Property, Plant and Equipment Software 3 Office equipment 5 Furniture and fixtures 5 Lab equipment 7 Leasehold improvements Term of lease

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Sep. 30, 2023
Investments, All Other Investments [Abstract]
Summary of Financial Instruments at Fair Value on Recurring Basis	The Company has certain financial instruments that must be measured under the new fair value standard. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of September 30, 2023 and 2022, respectively: Summary of Financial Instruments at Fair Value on Recurring Basis Level 1 Level 2 Level 3 Fair Value Measurements at September 30, 2023 Level 1 Level 2 Level 3 Assets Cash $ 271,006 $ - $ - Liabilities Notes payable - 565,000 - Convertible notes payable, net of discounts of $ 43,051 - - 1,725,184 Level 1 Level 2 Level 3 Fair Value Measurements at September 30, 2022 Level 1 Level 2 Level 3 Assets Cash $ 56,168 $ - $ - Liabilities Notes payable - 665,000 - Convertible notes payable, net of discounts of $ 84,767 - - 1,683,467

Fixed Assets (Tables)

Fixed Assets (Tables)	12 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets consist of the following at September 30, 2023 and 2022: Schedule of Fixed Assets 2023 2022 As of September 30, September 30, 2023 2022 Lab equipment $ - $ 55,000 Fixed assets, gross - 55,000 Less: accumulated depreciation - - Total $ - $ 55,000

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Schedule of Notes Payable	Notes payable consists of the following at September 30, 2023 and 2022, respectively: Schedule of Notes Payable September 30, September 30, On September 10, 2021, the Company issued a Secured Promissory note in the principal amount of $ 675,000 12 September 10, 2024 22,419.66 115,000 125,000 $ 665,000 $ 665,000 Total notes payable 665,000 665,000 Less: current maturities (665,000 ) (665,000 ) Notes payable $ - $ - The Company recorded interest expense pursuant to the stated interest rate and closing costs on the notes payable in the amount of $ 79,800 45,444 Notes payable – discontinued operations On December 26, 2019, the Company financed the purchase of $ 377,124 291,931 5.75 5,622 five-year December 26, 2024 $ 80,428 $ 141,348

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	12 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Schedule of Related Party Convertible Notes Payable	Related party convertible notes payable consist of the following at September 30, 2023 and September 30, 2022, respectively: Schedule of Related Party Convertible Notes Payable September 30, September 30, 2023 2022 On February 10, 2020, the Company completed the sale to an accredited investor of a 9% Secured Convertible Promissory Note in the principal amount of $ 350,000 August 10, 2022 9 0.15 0.03 50,000 400,000 50,000 1,666,667 0.03 February 11, 2024 4,550,000 43,788 As a result of the shares issued upon the extension agreement, the lender now holds more the 5% of the total outstanding common shares, and is therefore considered a related party $ 350,000 $ 350,000 Total related party convertible notes payable 350,000 350,000 Less: unamortized debt discounts (10,748 ) (39,728 ) Total convertible debt 339,252 310,272 Less: current maturities (339,252 ) - Related party convertible notes payable $ - $ 310,272
Schedule of Convertible Notes Payable	Convertible notes payable consist of the following at September 30, 2023 and 2022, respectively: Schedule of Convertible Notes Payable September 30, September 30, 2023 2022 On February 11, 2020, the Company completed the sale to an accredited investor of a 9% Secured Convertible Promissory Note in the principal amount of $ 50,000 August 11, 2022 9 0.15 0.03 10,000 60,000 10,000 333,334 0.03 February 11, 2024 650,000 6,989 $ 50,000 $ 50,000 On February 11, 2020, the Company completed the sale to an accredited investor of a 9% Secured Subordinated Convertible Promissory Note in the principal amount of $ 150,000 August 11, 2022 9 0.15 0.03 50,000 200,000 50,000 1,666,667 0.03 February 11, 2024 1,950,000 20,968 150,000 150,000 On September 23, 2019, the Company received proceeds of $ 200,000 8 August 10, 2022 0.11 August 10, 2022 0.03 90,000 3,000,000 0.03 355,469 98,188 February 11, 2024 4,621,105 32,166 355,469 355,469 On November 8, 2018, the Company received proceeds of $ 350,000 8 August 10, 2022 0.14 August 10, 2022 0.03 February 11, 2024 4,550,000 31,671 350,000 350,000 On October 1, 2022, the Company entered into a senior secured convertible note that carries an 8 February 11, 2024 362,765 0.01 4,715,945 30,102 362,765 362,765 On November 5, 2018, the Company received proceeds of $ 150,000 8 August 10, 2022 0.14 August 10, 2022 0.03 150,000 150,000 Total convertible notes payable 1,418,234 1,418,234 Less: unamortized debt discounts (32,302 ) (45,039 ) Total convertible debt 1,385,932 1,373,195 Less: current maturities (1,385,932 ) (1,198,469 ) Convertible notes payable $ - $ 174,726
Schedule of Interest Expense	The Company recognized interest expense for the years ended September 30, 2023 and 2022, respectively, as follows: Schedule of Interest Expense September 30, September 30, Interest on notes payable $ 79,800 $ 45,444 Amortization of beneficial conversion features 135,655 85,166 Interest on convertible notes 148,812 113,976 Total interest expense $ 364,267 $ 244,586

Common Stock Options (Tables)

Common Stock Options (Tables)	12 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Summary of Common Stock Options Outstanding	The following is a summary of information about the stock options outstanding at September 30, 2023. Summary of Common Stock Options Outstanding Shares Underlying Shares Underlying Options Outstanding Options Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Options Contractual Exercise Options Exercise Prices Outstanding Life Price Exercisable Price $ 0.0056 0.13 8,120,000 5.03 $ 0.052 6,020,000 $ 0.069
Schedule of Weighted-Average Assumptions Used for Grants	The fair value of each option grant is estimated on the date of grant using the Black-Scholes Option Pricing Model with the following weighted-average assumptions used for grants under the fixed option plan: Schedule of Weighted-Average Assumptions Used for Grants September 30, September 30, 2023 2022 Average risk-free interest rates 3.88 % 1.21 % Average expected life (in years) 2.9 5.00 Volatility 184.34 % 143 %
Schedule of Activity of Outstanding Common Stock Options	The following is a summary of activity of outstanding common stock options: Schedule of Activity of Outstanding Common Stock Options Weighted Average Number Exercise of Shares Price Balance, September 30, 2021 5,620,000 $ 0.08 Options issued 1,000,000 0.02 Options repurchased/expired (600,000 ) (0.11 ) Balance, September 30, 2022 6,020,000 $ 0.069 Options issued 2,100,000 0.006 Options forfeited - - Balance, September 30, 2023 8,120,000 $ 0.052 Exercisable, September 30, 2023 6,020,000 $ 0.069

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	12 Months Ended
	Sep. 30, 2023
Common Stock Warrants
Summary of Common Stock Warrants Outstanding	The following is a summary of information about our warrants to purchase common stock outstanding at September 30, 2023 (including those issued to both investors and service providers). Summary of Common Stock Warrants Outstanding Shares Underlying Shares Underlying Warrants Outstanding Warrants Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Warrants Contractual Exercise Warrants Exercise Prices Outstanding Life Price Exercisable Price $ 0.0074 0.10 15,387,050 8.76 $ 0.016 15,387,050 $ 0.016
Schedule of Outstanding Common Stock Warrants Activity	The following is a summary of activity of outstanding common stock warrants: Schedule of Outstanding Common Stock Warrants Activity Weighted Average Number Exercise of Shares Price Balance, September 30, 2021 2,535,001 $ 0.17 Warrants granted - - Warrants expired (1,035,001 ) (0.26 ) Balance, September 30, 2022 1,500,000 $ 0.10 Warrants granted 13,887,050 .007 Warrants expired - - Balance, September 30, 2023 15,387,050 $ 0.016 Exercisable, September 30, 2023 15,387,050 $ 0.016

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Sep. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Discontinued Operations Income Statement Balance Sheet and Additional Disclosures	The balance sheets of Digipath Labs are summarized below: Schedule of Discontinued Operations Income Statement Balance Sheet and Additional Disclosures September 30, 2023 September 30, 2022 Current assets: Accounts receivable, net $ 447,410 $ 335,085 Deposits 18,675 25,141 Other current assets 20,137 32,971 Total current assets 486,222 393,197 Right-of-use asset 274,985 316,961 Fixed assets, net 368,681 405,823 Total long term assets 643,666 722,784 Total Assets $ 1,129,888 $ 1,115,981 Current liabilities: Accounts payable $ 158,869 $ 283,098 Accrued expenses 61,512 32,571 Current portion of operating lease liabilities 83,757 100,685 Current maturities of notes payable 64,517 60,920 Total current liabilities 368,655 477,274 Operating lease liabilities 143,245 229,825 Notes payable 15,911 80,428 Total long term liabilities 159,156 310,253 Total Liabilities $ 527,811 $ 787,527 The statements of operations of Digipath Labs combined are summarized below: 2023 2022 For the Years Ended September 30, 2023 2022 Revenues $ 3,330,704 $ 2,699,920 Cost of sales 1,736,401 1,633,972 Gross profit 1,594,303 1,065,948 Operating expenses: General and administrative 883,781 927,671 Professional fees 98,352 2,157 Total operating expenses 982,133 929,828 Operating income(loss) 612,170 136,120 Other income (expense): Other income 322,798 - Interest expense (6,539 ) (15,687 ) Total other income (expense) 316,259 (15,687 ) Net income (loss) $ 928,429 $ 120,433

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate	The effective income tax rate for the years ended September 30, 2023 and 2022 consisted of the following: Schedule of Effective Income Tax Rate 2023 2022 September 30, 2023 2022 Federal statutory income tax rate 21 % 21 % State income taxes - % - % Change in valuation allowance (21 )% (21 )% Net effective income tax rate - -
Schedule of Deferred Tax Asset	The components of the Company’s deferred tax asset are as follows: Schedule of Deferred Tax Asset 2023 2022 September 30, 2023 2022 Deferred tax assets: Net operating loss carry forwards $ 2,960,100 $ 3,130,800 Net deferred tax assets before valuation allowance $ 2,960,100 $ 3,130,800 Less: Valuation allowance (2,960,100 ) (3,130,800 ) Net deferred tax assets $ - $ -

Schedule of Entities Under Comm

Schedule of Entities Under Common Control and Ownership (Details)	12 Months Ended
	Sep. 30, 2023
Entities Under Common Control and Ownership One [Member]
Name of Entity	Digipath, Inc	[1]
Jurisdiction of Incorporation	Nevada
Relationship	Parent
Entities Under Common Control and Ownership Two [Member]
Name of Entity	Digipath Labs, Inc
Jurisdiction of Incorporation	Nevada
Relationship	Subsidiary
Entities Under Common Control and Ownership Three [Member]
Name of Entity	Digipath Labs CA, Inc	[2]
Jurisdiction of Incorporation	California
Relationship	Subsidiary
Entities Under Common Control and Ownership Four [Member]
Name of Entity	Digipath Labs S.A.S	[3]
Jurisdiction of Incorporation	Colombia
Relationship	Subsidiary
Entities Under Common Control and Ownership Five [Member]
Name of Entity	VSSL Enterprises, Ltd	[4]
Jurisdiction of Incorporation	Canada
Relationship	Subsidiary
[1]Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company.[2]Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations and has no significant assets.[3]Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations and has no significant assets.[4]Acquired on March 11, 2020.

Schedule of Estimated Useful Li

Schedule of Estimated Useful Lives of Property, Plant and Equipment (Details)	Sep. 30, 2023
Computer Software, Intangible Asset [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	7 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]	Useful Life, Lease Term [Member]

Nature of Business and Signif_4

Nature of Business and Significant Accounting Policies (Details Narrative) - USD ($)		12 Months Ended
	Apr. 20, 2023	Sep. 30, 2023	Sep. 30, 2022
Schedule of Equity Method Investments [Line Items]
Accounts Receivable, Allowance for Credit Loss		$ 154,179	$ 139,279
Allowance for credit losses		720,000	931,665
Cash purchase price		275,000	175,000
Advertising expense		$ 4,444	$ 58,739
Conversion of preferred shares		8,340,000
Series A Convertible Preferred Stock [Member]
Schedule of Equity Method Investments [Line Items]
Conversion of preferred shares		13,579,710	13,579,710
Convertible Debt Securities [Member]
Schedule of Equity Method Investments [Line Items]
Antidilutive securities earning per share		83,125,488	58,941,155
Share-Based Payment Arrangement, Option [Member]
Schedule of Equity Method Investments [Line Items]
Antidilutive securities earning per share		8,120,000	6,020,000
Warrant [Member]
Schedule of Equity Method Investments [Line Items]
Antidilutive securities earning per share		15,387,050	1,500,000
Discontinued Operations, Held-for-Sale [Member] | Purchase Agreement [Member]
Schedule of Equity Method Investments [Line Items]
Cash purchase price	$ 2,300,000

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Sep. 30, 2023	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 19,761,997	$ 20,008,771

Summary of Financial Instrument

Summary of Financial Instruments at Fair Value on Recurring Basis (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2022
Fair Value, Inputs, Level 1 [Member]
Platform Operator, Crypto-Asset [Line Items]
Cash	$ 271,006	$ 56,168
Notes payable
Convertible notes payable, net of discounts of $84,767
Fair Value, Inputs, Level 2 [Member]
Platform Operator, Crypto-Asset [Line Items]
Cash
Notes payable	565,000	665,000
Convertible notes payable, net of discounts of $84,767
Fair Value, Inputs, Level 3 [Member]
Platform Operator, Crypto-Asset [Line Items]
Cash
Notes payable
Convertible notes payable, net of discounts of $84,767	$ 1,725,184	$ 1,683,467

Summary of Financial Instrume_2

Summary of Financial Instruments at Fair Value on Recurring Basis (Details) (Parenthetical) - USD ($)	Sep. 30, 2023	Sep. 30, 2022
Convertible Debt [Member]
Short-Term Debt [Line Items]
Convertible notes discounts	$ 43,051	$ 84,767

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Related Party Transaction [Line Items]
Compensation for services		$ 143,500
Officer [Member]
Related Party Transaction [Line Items]
Common stock granted	3,400,000
Compensation for services	$ 24,820
Directors [Member]
Related Party Transaction [Line Items]
Common stock granted	1,400,000
Director [Member]
Related Party Transaction [Line Items]
Common stock granted	1,400,000
Compensation for services	$ 9,860
Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Service for incurred fees	60,000
Service for incurred fees	111,437
Board Of Directors [Member]
Related Party Transaction [Line Items]
Service for incurred fees	34,000
Payment to directors	30,000
Payments waived off	138,000
Due to related party	10,000
Officer And Directors [Member]
Related Party Transaction [Line Items]
Reimbursable expenses	$ 2,390

Note Receivable (Details Narrat

Note Receivable (Details Narrative) - USD ($)						13 Months Ended
	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Dec. 08, 2022	Sep. 30, 2022	Aug. 23, 2021	Jun. 13, 2019
Financing Receivable, Modified [Line Items]
Purchase price note receivable						$ 100,000
Northwest Analytical Labs, Inc. [Member] | Related Party [Member]
Financing Receivable, Modified [Line Items]
Notes receivable								$ 95,000
Debt instrument stated percentage								10%
C3 Labs, Inc., [Member] | Related Party [Member]
Financing Receivable, Modified [Line Items]
Notes receivable						$ 1,056,570	$ 1,056,570
Debt instrument stated percentage						8%	8%
Debt instrument maturity date						Aug. 23, 2022
Interest receivable						$ 64,017
Invictus Wealth Group [Member] | Asset Purchase Agreement [Member]
Financing Receivable, Modified [Line Items]
Debt instrument stated percentage					10%
Debt instrument maturity date					Dec. 31, 2023
Purchase price note receivable					$ 900,000
Upfront payment					275,000
Purchase price note receivable					$ 625,000
Debt final payment			$ 100,000
Received portion of upfront payment				$ 275,000
Invictus Wealth Group [Member] | Asset Purchase Agreement [Member] | Forecast [Member]
Financing Receivable, Modified [Line Items]
Debt final payment		$ 425,000
Invictus Wealth Group [Member] | Asset Purchase Agreement [Member] | Forecast [Member] | Extended Maturity [Member]
Financing Receivable, Modified [Line Items]
Debt final payment	$ 425,000	$ 100,000

Schedule of Fixed Assets (Detai

Schedule of Fixed Assets (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Lab equipment		$ 55,000
Fixed assets, gross		55,000
Less: accumulated depreciation
Total		$ 55,000

Fixed Assets (Details Narrative

Fixed Assets (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Impairment expense	$ 55,000

Schedule of Notes Payable (Deta

Schedule of Notes Payable (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2022
Short-Term Debt [Line Items]
Total notes payable	$ 665,000	$ 665,000
Less: current maturities	(665,000)	(665,000)
Notes payable
Notes Payable [Member]
Short-Term Debt [Line Items]
Total notes payable	665,000	665,000
Notes Payable [Member] | Discontinued Operations [Member]
Short-Term Debt [Line Items]
Total notes payable	$ 80,428	$ 141,348

Schedule of Notes Payable (De_2

Schedule of Notes Payable (Details) (Parenthetical) - USD ($)			12 Months Ended
	Sep. 10, 2021	Dec. 26, 2019	Sep. 30, 2023	Sep. 30, 2022
Short-Term Debt [Line Items]
Repayments of notes payable			$ 100,000	$ 125,000
Canna Lab Note [Member]
Short-Term Debt [Line Items]
Principal amount	$ 675,000
Debt instrument stated percentage	12%
Debt instrument, maturity date	Sep. 10, 2024
Debt instrument periodic payment	$ 22,419.66
Secured Promissory Note [Member]
Short-Term Debt [Line Items]
Debt conversion original debt amount				115,000
Repayments of notes payable				$ 125,000
Note Payable [Member] | Discontinued Operations [Member]
Short-Term Debt [Line Items]
Debt instrument stated percentage		5.75%
Debt instrument, maturity date		Dec. 26, 2024
Debt instrument periodic payment		$ 5,622
Payments for lab equipment		377,124
Proceeds from bank loan		$ 291,931
Debt instrument term description		5 years

Schedule of Related Party Conve

Schedule of Related Party Convertible Notes Payable (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2022
Short-Term Debt [Line Items]
Total related party convertible notes payable	$ 1,418,234	$ 1,418,234
Total convertible debt	1,385,932	1,373,195
Less: current maturities	(1,385,932)	(1,198,469)
Related Party [Member]
Short-Term Debt [Line Items]
Total related party convertible notes payable	350,000	350,000
Less: unamortized debt discounts	(10,748)	(39,728)
Total convertible debt	339,252	310,272
Less: current maturities	(339,252)
Related party convertible notes payable		310,272
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Less: unamortized debt discounts	(43,050)
Convertible Notes Payable [Member] | Related Party [Member]
Short-Term Debt [Line Items]
Total related party convertible notes payable	$ 350,000	$ 350,000

Schedule of Related Party Con_2

Schedule of Related Party Convertible Notes Payable (Details) (Parenthetical) - USD ($)						12 Months Ended
	Aug. 08, 2022	Aug. 08, 2022	Dec. 29, 2020	Dec. 28, 2020	Feb. 11, 2020	Sep. 30, 2023	Sep. 30, 2022
Short-Term Debt [Line Items]
Proceeds from convertible debt							$ 402,765
Shares of common stock issued
Secured Subordinated Convertible Promissory Note [Member] | Accredited Investors [Member]
Short-Term Debt [Line Items]
Principal amount			$ 50,000	$ 400,000	$ 350,000
Maturity date		Feb. 11, 2024			Aug. 10, 2022
Debt instrument interest percentage					9%
Conversion price			$ 0.03	$ 0.03	$ 0.15
Proceeds from convertible debt				$ 50,000
Debt converted principal value, shares			1,666,667
Shares of common stock issued		4,550,000
Debt instrument fair value	$ 43,788	$ 43,788
Debt instrument agreement	As a result of the shares issued upon the extension agreement, the lender now holds more the 5% of the total outstanding common shares, and is therefore considered a related party

Schedule of Convertible Notes P

Schedule of Convertible Notes Payable (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2022
Short-Term Debt [Line Items]
Total convertible notes payable	$ 1,418,234	$ 1,418,234
Less: unamortized debt discounts	(32,302)	(45,039)
Total convertible debt	1,385,932	1,373,195
Less: current maturities	(1,385,932)	(1,198,469)
Nonrelated Party [Member]
Short-Term Debt [Line Items]
Convertible notes payable		174,726
Convertible Notes Payable One [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	50,000	50,000
Convertible Notes Payable Two [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	150,000	150,000
Convertible Notes Payable Three [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	355,469	355,469
Convertible Notes Payable Four [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	350,000	350,000
Convertible Notes Payable Five [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	362,765	362,765
Convertible Notes Payable Six [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	$ 150,000	$ 150,000

Schedule of Convertible Notes_2

Schedule of Convertible Notes Payable (Details) (Parenthetical) - USD ($)

12 Months Ended

Oct. 02, 2022

Aug. 08, 2022

Sep. 30, 2021

Feb. 22, 2021

Dec. 29, 2020

Dec. 28, 2020

Sep. 30, 2020

Feb. 11, 2020

Sep. 23, 2019

Nov. 08, 2018

Nov. 05, 2018

Sep. 30, 2023

Sep. 30, 2022

Short-Term Debt [Line Items]

Proceeds from convertible debt

$ 402,765

Shares issued

Amortization of debt discount premium

$ 135,655

$ 85,166

Debt instrument purchase of warrant

15,387,050

9% Secured Convertible Promissory Note [Member] | Accredited Investors [Member]

Short-Term Debt [Line Items]

Principal amount

$ 10,000

$ 60,000

$ 50,000

Maturity date

Feb. 11, 2024

Aug. 11, 2022

Debt instrument interest percentage

9%

Conversion price

$ 0.03

$ 0.03

$ 0.15

Proceeds from convertible debt

$ 10,000

Debt converted principal value, shares

333,334

Shares issued

650,000

Debt instrument fair value

$ 6,989

9% Secured Subordinated Convertible Promissory Note [Member] | Accredited Investors [Member]

Short-Term Debt [Line Items]

Principal amount

$ 200,000

$ 150,000

Maturity date

Feb. 11, 2024

Aug. 11, 2022

Debt instrument interest percentage

9%

Conversion price

$ 0.03

$ 0.03

$ 0.15

Proceeds from convertible debt

$ 50,000

Debt converted principal value, shares

1,666,667

Debt converted principal amount

$ 50,000

9% Secured Subordinated Convertible Promissory Note [Member] | Accredited Investors One [Member]

Short-Term Debt [Line Items]

Shares issued

1,950,000

Debt instrument fair value

$ 20,968

Senior Secured Convertible Note [Member]

Short-Term Debt [Line Items]

Maturity date

Feb. 11, 2024

Aug. 10, 2022

Aug. 10, 2022

Debt instrument interest percentage

8%

Conversion price

$ 0.03

$ 0.03

$ 0.11

Proceeds from convertible debt

$ 200,000

Debt converted principal value, shares

3,000,000

Debt converted principal amount

$ 90,000

Debt instrument periodic payment

$ 355,469

Amortization of debt discount premium

$ 98,188

Debt instrument purchase of warrant

4,621,105

Debt instrument fair value of warrant

$ 32,166

Senior Secured Convertible Note One [Member]

Short-Term Debt [Line Items]

Maturity date

Feb. 11, 2024

Aug. 10, 2022

Aug. 10, 2022

Debt instrument interest percentage

8%

Conversion price

$ 0.03

$ 0.14

Proceeds from convertible debt

$ 350,000

Debt instrument purchase of warrant

4,550,000

Debt instrument fair value of warrant

$ 31,671

Senior Secured Convertible Note Two [Member]

Short-Term Debt [Line Items]

Maturity date

Feb. 11, 2024

Debt instrument interest percentage

8%

Conversion price

$ 0.01

Debt instrument purchase of warrant

4,715,945

Debt instrument fair value of warrant

$ 30,102

Debt conversion original debt amount

$ 362,765

Senior Secured Convertible Note Three [Member]

Short-Term Debt [Line Items]

Maturity date

Aug. 10, 2022

Aug. 10, 2022

Debt instrument interest percentage

8%

Conversion price

$ 0.03

$ 0.14

Proceeds from convertible debt

$ 150,000

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Note Payable [Member]
Short-Term Debt [Line Items]
Interest expense	$ 79,800	$ 45,444

Schedule of Interest Expense (D

Schedule of Interest Expense (Details) - USD ($)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Debt Disclosure [Abstract]
Interest on notes payable	$ 79,800	$ 45,444
Amortization of beneficial conversion features	135,655	85,166
Interest on convertible notes	148,812	113,976
Total interest expense	$ 364,267	$ 244,586

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Short-Term Debt [Line Items]
Amortization of debt discounts	$ 135,655	$ 85,166
Maximum Share Amount [Member]
Short-Term Debt [Line Items]
Maximum amount owned percentage of issued and outstanding common shares	4.99%
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Debt discount conversion feature of convertible debt	$ 93,938
Amortization of debt discounts	135,655	85,166
Unamortized discounts	43,050
Convertible notes interest expense	$ 148,812	$ 113,976

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)			12 Months Ended
	Mar. 02, 2023	Jul. 25, 2022	Sep. 30, 2023	Sep. 30, 2022
Class of Stock [Line Items]
Preferred stock, shares authorized			10,000,000
Preferred stock, par value			$ 0.001
Shares converted value				$ (85,846)
Stock repurchased, value			$ 100
Common stock, par value			$ 0.001	$ 0.001
Common stock, shares authorized			250,000,000	250,000,000
Common stock, shares issued			87,096,820	75,146,820
Common stock, shares outstanding			87,096,820	75,146,820
Issuance of common shares to settle stock payable
Common stock issued for services, shares				$ 143,500
Common stock issued for services, shares				7,500
Common Stock [Member]
Class of Stock [Line Items]
Shares converted value
Stock repurchased, value
Issuance of common shares to settle stock payable, shares			7,150,000
Issuance of common shares to settle stock payable			$ 7,150
Common stock issued for services, shares				$ 3,667
Common stock issued for services, shares				3,666,667
Common stock issued for services, shares				250,000
Common stock issued for services, shares				$ 250
Officer [Member]
Class of Stock [Line Items]
Common stock granted			3,400,000
Common stock issued for services, shares			$ 24,820
Director [Member]
Class of Stock [Line Items]
Common stock granted			1,400,000
Common stock issued for services, shares			$ 9,860
Chief Financial Officer [Member] | Common Stock [Member]
Class of Stock [Line Items]
Common stock issued for services, shares				$ 52,500
Common stock issued for services, shares				1,500,000
Third Party Consultants [Member] | Common Stock [Member]
Class of Stock [Line Items]
Common stock issued for services, shares				$ 91,000
Common stock issued for services, shares				2,166,667
Common stock issued for services, shares				250,000
Common stock issued for services, shares				$ 7,500
Lenders [Member] | Common Stock [Member]
Class of Stock [Line Items]
Common stock issued for services, shares				7,150,000
Stock payable fair value				$ 71,745
Consultant [Member]
Class of Stock [Line Items]
Common stock issued for services, shares				3,666,667
Stock-based compensation expense				$ 143,500
Initial Investment [Member]
Class of Stock [Line Items]
Percentage of equity beneficial ownership				20%
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized			6,000,000	6,000,000
Preferred stock, par value			$ 0.001	$ 0.001
Preferred stock, shares issued			1,047,942	1,047,942
Preferred stock, shares outstanding			1,047,942	1,047,942
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Temporary equity, shares authorized			1,500,000	1,500,000
Temporary equity, shares issued			333,600	333,600
Temporary equity, shares outstanding			333,600	333,600
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized			1,000
Preferred stock, shares designated remaining			2,499,000
Preferred stock voting rights			the Company’s common stock on all matters presented to the holders of common stock, whether at a special or annual meeting, by written action in lieu of a meeting or otherwise, on the basis of 200,000 votes for each share of Series C Preferred
Preferred stock voting rights			$ 0.10
Stock repurchased, value	$ 100
Series C Preferred Stock [Member] | Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Conversion of stock shares converted		1,000
Share weighted average price of shares purchased		$ 0.10
Compensation expenses to officer		$ 360,200
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized			1,000	1,000
Preferred stock, par value			$ 0.001	$ 0.001
Preferred stock, shares issued			0	1,000
Preferred stock, shares outstanding			0	1,000
Temporary equity, shares issued			1,000
Temporary equity, shares outstanding			1,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Conversion of stock shares converted			1,047,942	2,780
Convertible shares			5,239,710
Common stock, terms of conversion			No holder is permitted to convert its shares of Series A Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice
Percentage of distribution on purchase price			100%
Cash proceed				$ 556
Shares invested				556
Shares converted value				$ 192,154
Series A Preferred Stock [Member] | Noteholders [Member]
Class of Stock [Line Items]
Percentage of equity beneficial ownership			4.99%
Common Stock [Member]
Class of Stock [Line Items]
Issuance of common shares to settle stock payable, shares			7,150,000
Issuance of common shares to settle stock payable			$ 71,745

Mezzanine Equity (Details Narra

Mezzanine Equity (Details Narrative) - USD ($)		12 Months Ended
	Dec. 30, 2021	Sep. 30, 2023	Sep. 30, 2022
Preferred stock, par value		$ 0.001
Conversion of stock shares issued		8,340,000
Purchase of Series B Preferred shares, shares
Share price		$ 0.015
Series B Preferred Stock [Member]
Preferred stock, par value		1
Conversion price		$ 0.04
Conversion shares converted		333,600
Common stock, terms of conversion		No holder is permitted to convert its shares of Series B Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice
Conversion of stock description		Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, or upon a change in control whereby a stockholder gains control of 50% or more of the outstanding shares of common stock, the shares of Series B Preferred are entitled to receive, prior to any distribution to the holders of common stock and the Series A Preferred, 100% of the purchase price per share of Series B Preferred plus all accrued but unpaid dividends
Series A Preferred [Member] | Exchange Agreement [Member]
Shares exchanged	278,000
Series B Preferred [Member] | Exchange Agreement [Member]
Shares exchanged	278,000
Series B Preferred [Member] | Exchange Agreement [Member] | Investor [Member]
Purchase of Series B Preferred shares, shares	55,600
Share price	$ 1
Shares purchased value	$ 55,600

Summary of Common Stock Options

Summary of Common Stock Options Outstanding (Details)	12 Months Ended
	Sep. 30, 2023 $ / shares shares
Share-Based Payment Arrangement [Abstract]
Range of Exercise Price, Minimum	$ 0.0056
Range of Exercise Price, Maximum	$ 0.13
Number of Options Outstanding | shares	8,120,000
Weighted Average Remaining Contractual Life	5 years 10 days
Weighted Average Exercise Price	$ 0.052
Number of Shares Exercisable | shares	6,020,000
Weighted Average Exercise Price Exercisable	$ 0.069

Schedule of Weighted-Average As

Schedule of Weighted-Average Assumptions Used for Grants (Details)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Average risk-free interest rates	3.88%	1.21%
Average expected life	2 years 10 months 24 days	5 years
Volatility	184.34%	143%

Schedule of Activity of Outstan

Schedule of Activity of Outstanding Common Stock Options (Details) - $ / shares	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Number of Shares Outstanding, Beginning balance	6,020,000	5,620,000
Weighted Average Exercise Price, Outstanding, Beginning	$ 0.069	$ 0.08
Number of Shares Options issued	2,100,000	1,000,000
Weighted Average Exercise Price, Options issued	$ 0.006	$ 0.02
Number of Shares Options repurchased/expired		(600,000)
Weighted Average Exercise Price, Options repurchased/expired		$ (0.11)
Number of Shares Options forfeited
Weighted Average Exercise Price, Options issued
Number of Shares Outstanding, Ending balance	8,120,000	6,020,000
Weighted Average Exercise Price, Outstanding, Ending	$ 0.052	$ 0.069
Number of Shares Exercisable, Ending	6,020,000
Weighted Average Exercise Price, Exercisable, Ending	$ 0.069

Common Stock Options (Details N

Common Stock Options (Details Narrative) - USD ($)		12 Months Ended
	Jun. 21, 2016	Sep. 30, 2023	Sep. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Volatility rate		184.34%	143%
Expected term		2 years 10 months 24 days	5 years
Weighted average fair value of options granted with exercise price		$ 0.006	$ 0.02
Intrinsic value , outstanding		$ 19,320
Market price, per share		$ 0.015
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average fair value of options granted with exercise price		$ 0.005
Amortization of Stock Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expenses		$ 24,474	$ 62,533
Unamortized expenses expected to be expensed		$ 1,153
2012 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Volatility rate		184%	143%
Call option values price		$ 0.00497	$ 0.021
Exercise prices		$ 0.0056	$ 0.024
Expected term		5 years 9 months
2012 Stock Incentive Plan [Member] | Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares issued to certain employees		2,100,000	1,000,000
Total fair value		$ 10,446	$ 20,994
2012 Stock Incentive Plan [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares issued under stock plan	11,500,000

Summary of Common Stock Warrant

Summary of Common Stock Warrants Outstanding (Details)	12 Months Ended
	Sep. 30, 2023 $ / shares shares
Common Stock Warrants
Exercise Price Range Lower Range	$ 0.0074
Exercise Price Range Upper Range	$ 0.10
Number of Warrants Outstanding | shares	15,387,050
Weighted Average Remaining Contractual Life	8 years 9 months 3 days
Weighted Average Exercise Price	$ 0.016
Number of Warrants Exercisable | shares	15,387,050
Weighted Average Exercise Price, Exercisable	$ 0.016

Schedule of Outstanding Common

Schedule of Outstanding Common Stock Warrants Activity (Details) - $ / shares	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Common Stock Warrants
Number of Shares, Balance beginning	1,500,000	2,535,001
Weighted Average Exercise Price, Balance beginning	$ 0.10	$ 0.17
Number of Shares, Warrants granted	13,887,050
Weighted Average Exercise Price, Warrants granted	$ 0.007
Number of Shares, Warrants expired		(1,035,001)
Weighted Average Exercise Price, Warrants expired		$ (0.26)
Number of Shares, Warrants expired		1,035,001
Number of Shares, Balance ending	15,387,050	1,500,000
Weighted Average Exercise Price, Balance, ending	$ 0.016	$ 0.10
Weighted Average Exercise Price, Balance, ending	15,387,050
Weighted Average Exercise Price, Exercisable	$ 0.016

Common Stock Warrants (Details

Common Stock Warrants (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Number of warrant to purchase of common stock shares	15,387,050
Warrant [Member]
Number of warrant to purchase of common stock shares	13,887,050	1,035,001
Weighted average exercise price	$ 0.007	$ 0.26
Warrants, intrinic value	$ 102,764
Intrinsic value, market price per share	$ 0.015

Schedule of Discontinued Operat

Schedule of Discontinued Operations Income Statement Balance Sheet and Additional Disclosures (Details) - USD ($)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Current assets:
Accounts receivable, net	$ 447,410	$ 335,085
Deposits	18,675	25,141
Other current assets	20,137	32,971
Total current assets	486,222	393,197
Right-of-use asset	274,985	316,961
Fixed assets, net	368,681	405,823
Total long term assets	643,666	722,784
Total Assets	1,129,888	1,115,981
Current liabilities:
Accounts payable	158,869	283,098
Accrued expenses	61,512	32,571
Current portion of operating lease liabilities	83,757	100,685
Current maturities of notes payable	64,517	60,920
Total current liabilities	368,655	477,274
Operating lease liabilities	143,245	229,825
Notes payable	15,911	80,428
Total long term liabilities	159,156	310,253
Total Liabilities	527,811	787,527
Revenues	3,330,704	2,699,920
Cost of sales	1,736,401	1,633,972
Gross profit	1,594,303	1,065,948
Operating expenses:
General and administrative	883,781	927,671
Professional fees	98,352	2,157
Total operating expenses	982,133	929,828
Operating income(loss)	612,170	136,120
Other income (expense):
Other income	322,798
Interest expense	(6,539)	(15,687)
Total other income (expense)	316,259	(15,687)
Net income (loss)	$ 928,429	$ 120,433

Discontinued Operations (Detail

Discontinued Operations (Details Narrative) - USD ($)			12 Months Ended
	Apr. 30, 2023	Apr. 20, 2023	Sep. 30, 2023	Sep. 30, 2022	Apr. 20, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash purchase price			$ 275,000	$ 175,000
Escrow deposits					$ 230,000
Purchase Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Working capital		$ 150,000
Management Services Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Description of collaborative arrangement	The effectiveness of the Management Services Agreement is subject to the approval of the CCB, which was obtained on October 17, 2023. Pursuant to the Management Services Agreement, after the payment of expenses to third parties and a payment of 15% of cash collections to Digipath (but not less than $15,000) in each month, Buyer will be entitled to a management fee of $10,000 per month. Any remaining cash generated from the operation of the Lab in any month will be payable 45% to the Buyer and 55% to the Company
Payment of cash collections	$ 15,000
Management fee	$ 10,000
Discontinued Operations, Held-for-Sale [Member] | Purchase Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash purchase price		$ 2,300,000

Schedule of Effective Income Ta

Schedule of Effective Income Tax Rate (Details)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Federal statutory income tax rate	21%	21%
State income taxes
Change in valuation allowance	(21.00%)	(21.00%)
Net effective income tax rate

Schedule of Deferred Tax Asset

Schedule of Deferred Tax Asset (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Net operating loss carry forwards	$ 2,960,100	$ 3,130,800
Net deferred tax assets before valuation allowance	2,960,100	3,130,800
Less: Valuation allowance	(2,960,100)	(3,130,800)
Net deferred tax assets

Income Tax (Details Narrative)

Income Tax (Details Narrative)	12 Months Ended
	Sep. 30, 2023 USD ($)
Income Tax Disclosure [Abstract]
Operating loss carryforwards	$ 14,096,000
Expire	2031
Unrecognized Tax Benefits	$ 0